NeoGenomics rises after BTIG upgrades to 'buy'
BUZZ-NeoGenomics rises after BTIG upgrades to 'buy' ** Cancer diagnostics co NeoGenomics NEO.O shares rise more than 4% to $19.92 in premarket trading
** BTIG raises rating to "buy" from "neutral"; PT at $28, implying a 46.4% upside to stock's last close, the highest BTIG has set for NEO since at least 2023
** Brokerage says Medicare now covers the RaDaR ST test for more uses, which could open up 40% or more of its market; also the PanTracer LBx blood test could add more growth
** Says NEO has beaten revenue estimates four quarters in a row, its patent dispute is largely resolved, and its early Q3 revenue came in ahead of expectations
** 9 of 12 brokerages rate the stock "buy" or above, 3 "hold"; median PT of $19.50 - LSEG-compiled data
** Up to last close, shares up 62.67% YTD
(Reporting by Miraanta Lowrance in Bengaluru)
Recent news on NeoGenomics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
NeoGenomics rises after BTIG upgrades to 'buy'
Brief: Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan
Brief: Neogenomics Receives Medicare Coverage For Radar St For Immunotherapy Treatment Response Monitoring